MedPath

PIK3CA

Generic Name
PIK3CA
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
JQ83GG8LT2
Background

PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).

Associated Conditions
-
Associated Therapies
-
curetoday.com
·

FDA Approves Itovebi Combo for Some With Advanced Breast Cancer

FDA approves Itovebi with Ibrance and Faslodex for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, based on INAVO120 trial results showing improved progression-free survival and objective response rate.
medpagetoday.com
·

PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer

FDA approves inavolisib (Itovebi) in combination with palbociclib and fulvestrant for locally advanced, PIK3CA-mutated, HR-positive/HER2-negative breast cancer. INAVO120 trial showed inavolisib more than doubled median progression-free survival (PFS) to 15 months from 7.3 months. Common adverse events include neutrophil, hemoglobin, and platelet decreases, and increases in fasting glucose and creatinine.
cancernetwork.com
·

FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer

FDA approves inavolisib combo with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer, based on INAVO120 trial data showing improved progression-free survival and response rates.
healio.com
·

FDA approves Itovebi regimen for advanced breast cancer

FDA approves inavolisib (Itovebi) with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, based on INAVO120 trial results showing improved PFS, ORR, and duration of response.
mskcc.org
·

FDA Approves New Drug Combination for ER+, HER2- Breast Cancer

FDA approves inavolisib triplet therapy for ER+/HER2- breast cancer with PIK3CA mutation, significantly extending progression-free survival in phase 3 trial.
pharmacytimes.com
·

FDA Approves Inavolisib With Palbociclib and Fulvestrant for Breast Cancer

The FDA approved inavolisib in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer. The FoundationOne Liquid CDx assay was also approved as a companion diagnostic. The approval was based on the INAVO120 trial, showing median PFS of 15 months vs. 7.3 months with ORR of 58% vs. 25%. Common adverse reactions included decreased neutrophils, decreased hemoglobin, and increased fasting glucose.
oncnursingnews.com
·

FDA Approves Inavolisib Regimen for PIK3CA-mutated, HR+, HER2— Breast Cancer

The FDA approved inavolisib (Itovebi) plus palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer. The approval is based on the INAVO120 trial, showing improved progression-free survival (PFS) and objective response rate (ORR) with inavolisib. Common adverse events included decreased neutrophils, hemoglobin, and platelets, and increased fasting glucose and creatinine.
© Copyright 2025. All Rights Reserved by MedPath